HIF1-driven TDP-43 stabilizes TRIP6 mRNA to drive angiogenesis and colorectal cancer progression under hypoxia Authors: Ke Cheng, Yonggang Liu, Weiyu Feng, Dongli Xu, Bin Hao Published: 2026 ABSTRACT Highlights•Hypoxia induces TDP-43 via HIF-1α binding to HRE3 in its promoter.•TDP-43 stabilizes TRIP6 mRNA through RRM domain-mediated interaction.•TARDBP knockdown suppresses CRC metastasis and angiogenesis in vitro and in vivo.•TRIP6 rescues malignant phenotypes inhibited by TARDBP silencing. Introduction Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, with tumor metastasis being the primary cause of treatment failure and poor prognosis [1]. The tumor microenvironment (TME) plays a critical role in driving cancer progression, and hypoxia is a key hallmark of advanced solid tumors [2]. Rapidly proliferating cancer cells outstrip the oxygen supply from existing vasculature, creating hypoxic regions that activate adaptive signaling pathways [3]. Clinically, tumor hypoxia has been directly linked to more aggressive phenotypes and poor patient outcomes. For instance, studies using 18F-fluoromisonidazole (FMISO) PET imaging have demonstrated that significant hypoxia is a robust indicator of increased distant metastasis risk and higher rates of disease progression [4,5]. Furthermore, hypoxia has been identified as an independent predictor of poor overall survival (OS) in various clinical cohorts [6]. The master regulator of cellular response to hypoxia, hypoxia-inducible factor-1α (HIF-1α), orchestrates the expression of numerous genes promoting angiogenesis, metabolic reprogramming, and invasion [7]. Notably, tumor angiogenesis, stimulated by hypoxia-induced factors like VEGF, is essential for supplying nutrients and oxygen, thereby facilitating tumor growth and metastatic spread. Despite the established role of hypoxia in CRC aggressiveness, the complete repertoire of downstream effectors and the intricate molecular networks linking hypoxia to CRC metastasis remain incompletely elucidated. TAR DNA-binding protein 43 (TDP-43), encoded by the TARDBP gene, is a multifunctional RNA-binding protein predominantly known for its role in neurodegenerative diseases [8,9]. However, emerging evidence suggests an oncogenic function for TDP-43 in various cancers, where it regulates gene expression at multiple levels, including mRNA stability and alternative splicing [10]. TDP-43 contains two RNA recognition motifs (RRM1 and RRM2) that mediate its binding to target RNAs. While TDP-43 has been implicated in cancer cell survival and proliferation [11,12], its specific role in the hypoxic TME of CRC, particularly in regulating angiogenesis and metastasis, is largely unexplored. Furthermore, whether TDP-43 serves as a functional downstream effector of HIF-1α and the identity of its key mRNA targets in this context are unknown. Based on bioinformatic, molecular biological, and in vivo models, this study aims to systematically elucidate the critical role and underlying mechanisms of the HIF1/TARDBP axis in hypoxia-driven CRC progression. Specifically, this study aimed to: [1] elucidate the molecular mechanism by which HIF1 transcriptionally activates TARDBP expression in CRC cells under hypoxic conditions; [2] evaluate the functional necessity of the HIF1/TARDBP axis in driving malignant phenotypes, including proliferation, migration, invasion, and angiogenesis, both in vitro and in vivo; and [3] identify and characterize the critical downstream mRNA targets, specifically TRIP6, that mediate the pro-oncogenic and pro-angiogenic effects of the TDP-43 signaling cascade. These findings reveal a novel hypoxia-associated signaling pathway, providing new insights into the pathogenesis of colorectal cancer and suggesting potential therapeutic targets for advanced stages of the disease. Materials and methods Bioinformatic analysis The mRNA expression data of TARDBP (encoding TDP-43) and HIF1A in CRC and adjacent normal tissues were obtained from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). The protein expression level of TDP-43 in colon cancer was analyzed using data from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) via the UALCAN portal (http://ualcan.path.uab.edu). The correlation between TARDBP and HIF1A mRNA expression in TCGA CRC samples was evaluated using Pearson’s correlation analysis. The potential mRNA targets of TDP-43 were predicted using the ENCORI (Starbase) database (https://rnasysu.com/encori/index.php). Differentially expressed genes (DEGs) in CRC (|log2FC|>1, Padj < 0.05) and prognosis-related genes (P < 0.01) were identified from the TCGA-COAD dataset. A Venn diagram was generated to identify the overlapping genes among these three datasets for further analysis. Cell culture and hypoxic exposure The human colorectal cancer cell lines SW480 and HCT116, and the human embryonic kidney cell line HEK293T were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. All cells were maintained at 37°C in a humidified incubator with 5% CO2. For hypoxic treatments, cells were placed in a multi-gas incubator set to 1% O2, 5% CO2, and 94% N2 for the indicated durations. Cells in the logarithmic growth phase were used for all experiments. Cell transfection For gene knockdown, short hairpin RNAs (shRNAs) targeting human TARDBP (shTARDBP), HIF1A (shHIF1A), or non-targeting negative controls (shNC) were designed and synthesized by Miaoling Bio (Wuhan, China). For gene overexpression, the full-length coding sequences of human TARDBP, HIF1A, and TRIP6 were cloned into pcDNA3.1 vectors. A series of HA-tagged TARDBP truncation mutants (including ΔRRM1, ΔRRM2, and ΔRRM1&2) were constructed based on the wild-type plasmid. All plasmids were verified by DNA sequencing. Transient transfection of shRNAs or plasmid vectors was performed using Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer’s instructions. Reverse transcription quantitative real-time PCR (RT-qPCR) Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. RNA concentration and purity were measured using a NanoDrop 2000C spectrophotometer (Thermo Scientific). Genomic DNA was removed and first-strand cDNA was synthesized from 1 μg of total RNA using the SweScript RT II First Strand cDNA Synthesis Kit (Servicebio) with oligo (dT)18 primers. Quantitative real-time PCR was performed using the ArtiCanATM SYBR qPCR Mix (Tsingke Biotechnology) on a QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems). The PCR cycling conditions were as follows: 95°C for 60 s, followed by 40 cycles of 95°C for 10 s and 60°C for 20 s. All reactions were performed in triplicate. Gene expression levels were calculated using the 2–ΔΔCt method with normalization to β-actin. The primer sequences used were as follows: TARDBP forward, 5’-TCCAAAAGATAACAAAAGAAAAATG-3’ and reverse, 5’-TCCATCTATCATATGTCGCTGTG-3’; HIF1A forward, 5’-AGGACAAGTCACCACAGGACAGTAC-3’ and reverse, 5’-CTGGGGCCAGCAAAGTTAAAG-3’; TRIP6 forward, 5’-CCCACCCCAGGGTCAATTTT-3’ and reverse, 5’-CAGCAAGTCTATCTCGGCGT-3’; β-actin forward, 5’-GGAGATGAGGCTCAGAGCAAG-3’ and reverse, 5’-GCTCATCTGGTGCCACACG-3’. Western blot analysis Total protein was extracted from cells using Western blot/IP lysis buffer (Beyotime) supplemented with protease inhibitor cocktail (Beyotime). Protein concentration was determined using a BCA protein assay kit (Beyotime). Equal amounts of protein (30 μg) were separated by 10% SDS-PAGE and then transferred onto PVDF membranes (Millipore). The membranes were blocked with 5% non-fat milk in TBST for 2 h at room temperature and subsequently incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: anti-TDP-43 (#10782-2-AP, Proteintech), anti-HIF-1α (#20960-1-AP, Proteintech), anti-TRIP6 (#60205-1-Ig, Proteintech), anti-HA (#51064-2-AP, Proteintech), anti-β-actin (#66009-1-Ig, Proteintech). After washing with TBST, membranes were incubated with HRP-conjugated secondary antibodies for 2 h at 37°C. Protein bands were visualized using an enhanced chemiluminescence (ECL) kit (Beyotime) and imaged with a ChampChemi 610 imaging system (Saizhi Group). β-actin was used as a loading control. Dual-luciferase reporter assay To investigate the transcriptional regulation of TARDBP by HIF-1α, dual-luciferase reporter assays were performed. The promoter region of human TARDBP was cloned into the pGL4-Basic vector (Promega) upstream of the firefly luciferase gene. A series of 5’-truncation mutants of the TARDBP promoter were constructed to identify functional hypoxia-response elements (HREs). HEK293T cells were co-transfected with the promoter-reporter constructs and either a HIF1A overexpression plasmid (HIF1A) or an empty vector control (Vec), using a Renilla luciferase vector (pRL-TK) as an internal control. Transfections were carried out with Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions. After 48 h of incubation, firefly and Renilla luciferase activities were measured sequentially using the Dual-Luciferase® Reporter Assay System (Promega) on a microplate luminometer. The relative promoter activity was calculated as the ratio of firefly luciferase activity to Renilla luciferase activity. All experiments were performed in triplicate. Chromatin immunoprecipitation (ChIP)-qPCR ChIP was performed using the SimpleChIP® Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to the manufacturer’s instructions. Briefly, SW480 and HCT116 cells were cross-linked with 1% formaldehyde for 10 min at room temperature, followed by quenching with glycine. Cells were lysed and chromatin was fragmented by enzymatic digestion to obtain DNA fragments of 200-1000 bp. The chromatin was immunoprecipitated overnight at 4°C with an anti-HIF-1α antibody (#20960-1-AP, Proteintech) or normal rabbit IgG as a negative control. Protein-DNA complexes were captured using Protein A/G Magnetic Beads, followed by extensive washing. After reverse cross-linking and DNA purification, the enriched DNA fragments were analyzed by qPCR using primers specific for the putative HRE regions in the TDP-43 promoter. The primer sequences used were as follows: HRE1 forward, 5’-AAATTAGCCGGGCGTGGT-3’ and reverse, 5’-CTCCCGGGTTCACTCTATTCTC-3’; HRE2 forward, 5’-AGAGTGAACCCGGGAGGCG-3’ and reverse, 5’-TTGAGATGGAGTCTCGCTC-3’; HRE3 forward, 5’-GAAATGTGAAACAAAGGCCGG-3’ and reverse, 5’-TGTTGGCCAGGCTGGTCTC-3’. The results are presented as percentage of input. Cell proliferation assay Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8; Beyotime) according to the manufacturer’s instructions. Briefly, HCT116 and SW480 cells were seeded into 96-well plates at a density of 1 × 104 cells per well and subjected to the respective experimental treatments. After incubation for the indicated time periods, 10 µL of CCK-8 reagent was added to each well, followed by incubation at 37 °C for 1 h. The absorbance at 450 nm was measured using a microplate reader (Thermo Scientific). All experiments were performed with five replicates per condition. Cell migration and invasion assays Cell migration and invasion abilities were assessed using Transwell chambers (8-μm pore size; Corning). For the invasion assay, the upper chamber was pre-coated with 100 μL of Matrigel (diluted 1:8 in serum-free medium; BD Biosciences) and incubated at 37°C for 5 h to form a matrix layer. For both assays, after respective treatments, HCT116 and SW480 cells were resuspended in serum-free medium and seeded into the upper chamber at a density of 2 × 105 cells/mL. The lower chamber was filled with medium containing 20% FBS as a chemoattractant. After 24 h of incubation, non-migrated or non-invaded cells on the upper surface were removed with a cotton swab. Cells on the lower membrane were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and imaged under a microscope. The number of migrated or invaded cells was counted in five randomly selected fields per chamber. Chicken chorioallantoic membrane (CAM) assay The pro-angiogenic activity of CRC cells was evaluated using a CAM assay. Fertilized specific-pathogen-free (SPF) chicken eggs were incubated at 38°C and 65-70% relative humidity for 7 d. A small window was carefully opened in the eggshell above the air sac to expose the CAM. Sterile silicone rings were placed on the CAM, and HCT116 or SW480 cells (1 × 106 cells per egg) subjected to the indicated treatments were implanted onto the CAM within the rings. The windows were sealed with sterile adhesive tape, and the eggs were returned to the incubator for an additional 5 d. The CAMs were then photographed under a stereomicroscope. Angiogenesis was quantified by measuring the total vessel length and branch points within the ring area using ImageJ software (National Institutes of Health). Measurement of vascular endothelial growth factor (VEGF) secretion The concentration of VEGF in cell culture supernatants was quantified using a commercial human VEGF ELISA kit (#GEH0022, Servicebio) according to the manufacturer’s instructions. Briefly, cell culture supernatants were collected and centrifuged to remove debris. Standards and samples were added to the pre-coated microplate and incubated for 2 h at room temperature with shaking. After washing, a biotinylated detection antibody was added and incubated for 1 h, followed by incubation with streptavidin-HRP conjugate for 30 min. The plate was developed with TMB substrate, and the reaction was stopped with sulfuric acid. The absorbance was measured at 450 nm using a microplate reader, and VEGF concentrations were determined by interpolation from the standard curve. All samples were assayed in triplicate. Animal housing All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Second Clinical College of Zhengzhou University and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Female BALB/c nude mice (6 weeks old) were purchased from Beijing Huafukang Biotechnology Co., Ltd. (Beijing, China). Mice were housed under specific pathogen-free (SPF) conditions with a 12 h light/dark cycle, controlled temperature (22±2°C), and humidity (50±10%). Food and water were provided ad libitum. All efforts were made to minimize animal suffering. In vivo xenograft tumor assay HCT116 cells were cultured under normoxic or hypoxic (1% O2, 24 h) conditions. Cells were harvested and resuspended in PBS. A total of 5 × 106 cells in 100 μL suspension were subcutaneously injected into the right flank of each mouse. Mice were randomly divided into four groups (n=5 per group): [1] Normoxia (cells cultured under normoxia); [2] Hypoxia (cells cultured under hypoxia); [3] Hypoxia+shNC (cells transfected with non-targeting shRNA and cultured under hypoxia); [4] Hypoxia+shTARDBP (cells transfected with TARDBP-targeting shRNA and cultured under hypoxia). Tumor volume was measured weekly using a caliper and calculated by the formula: Volume=(length × width2)/2. After 5 weeks, mice were euthanized by cervical dislocation, and tumors were excised and weighed for further analysis. Immunohistochemistry (IHC) assay Tumor tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned at a thickness of 5 μm. After deparaffinization and rehydration, antigen retrieval was performed using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0). Endogenous peroxidase activity was blocked with 3% H2O2 for 25 min. Sections were incubated with 3% BSA for 30 min to block nonspecific binding, followed by incubation with primary antibodies against Ki-67 (#GB121141-50, Servicebio), VEGF (#GB15165-100, Servicebio), or MMP-9 (#GB12132-50, Servicebio) at 4°C overnight. After washing, sections were incubated with HRP-conjugated secondary antibody at room temperature for 50 min. Antigen detection was performed using DAB substrate, and nuclei were counterstained with hematoxylin. Sections were dehydrated, cleared, and mounted. Images were captured using a light microscope (Nikon Eclipse Ci), and the percentage of positive cells was quantified using ImageJ software. RNA immunoprecipitation and qPCR (RIP-qPCR) RIP assays were performed using the Magna RIPTM RNA-Binding Protein Immunoprecipitation Kit (Millipore) according to the manufacturer’s instructions. Briefly, SW480 and HCT116 cells were lysed in RIP lysis buffer containing protease and RNase inhibitors. Lysates were incubated with magnetic beads conjugated with anti-TDP-43 antibody (#10782-2-AP, Proteintech) or normal IgG (negative control) overnight at 4°C. For the domain mapping experiment, cells were transfected with plasmids encoding HA-tagged wild-type or truncated TARDBP (ΔRRM1, ΔRRM2, and ΔRRM1&2) prior to lysis, and IP was performed using anti-HA antibody. After extensive washing, co-precipitated RNAs were extracted using TRIzol reagent and reverse-transcribed into cDNA. The enrichment of TRIP6 mRNA was quantified by qPCR using gene-specific primers and SYBR Green mix (Tsingke Biotechnology). Data were expressed as fold enrichment relative to input samples. mRNA stability assay To assess the effect of TDP-43 on TRIP6 mRNA stability, SW480 and HCT116 cells were transfected with shNC or shTARDBP. Forty-eight hours post-transfection, transcription was halted by the addition of actinomycin D (5 μg/mL; Sigma-Aldrich). Total RNA was isolated at 0, 4, 8, and 12 h post-treatment using TRIzol reagent (Invitrogen). RNA concentration and purity were determined using a NanoDrop 2000 spectrophotometer (Thermo Scientific). cDNA was synthesized from 1 μg of total RNA using the SweScript RT II First Strand cDNA Synthesis Kit (Servicebio). Quantitative real-time PCR was performed using ArtiCanATM SYBR qPCR Mix (Tsingke Biotechnology) on an ABI QuantStudio6 Flex Real-Time PCR System. The relative abundance of TRIP6 mRNA was normalized to β-actin and calculated using the 2–ΔΔCt method. Data analysis All quantitative data are presented as the mean ± standard deviation (SD) from at least three independent experiments. Statistical analysis was performed using GraphPad Prism software (version 10.0). Prior to statistical analysis, the normality of the data distribution was assessed using the Shapiro-Wilk test. Comparisons between two groups were analyzed using the unpaired Student’s t-test. Comparisons among multiple groups were analyzed by one-way or two-way analysis of variance (ANOVA) followed by Tukey’s post hoc test, which specifically accounts for multiple comparisons to prevent mass significance errors. A P-value of less than 0.05 was considered statistically significant. Results TARDBP is upregulated in CRC and correlates with HIF1A expression We first evaluated the clinical significance of TDP-43 in CRC by analyzing public datasets to determine whether its expression is altered in tumor tissues and associated with hypoxia-related signaling. Analysis of TCGA RNA-seq data revealed that TARDBP mRNA levels were significantly elevated in CRC tissues compared to adjacent normal tissues (Fig. 1A). Consistent with this finding, protein expression data from the CPTAC confirmed a significant increase in TDP-43 protein levels in colon tumors (Fig. 1B). Given the central role of hypoxia and its master regulator HIF-1α in cancer progression, we further examined their relationship. Notably, correlation analysis demonstrated a significant positive association between TARDBP and HIF1A mRNA expression in CRC cohorts (Pearson R=0.277, P < 0.001) (Fig. 1C). While this relatively weak correlation likely reflects the cellular heterogeneity and temporal dynamics inherent to bulk tumor transcriptomic data, it provided the initial clinical rationale to investigate a potential regulatory relationship between HIF1A and TARDBP. This hypothesis was subsequently validated through direct mechanistic experiments, as described below.Fig. 1TARDBP is upregulated in colorectal cancer and its expression correlates with HIF1A. (A) Analysis of TARDBP mRNA expression in CRC and adjacent normal tissues from the TCGA database. Data are presented as log2(FPKM+1). Statistical significance was determined by unpaired t-test. (n-tumor=698, n-normal=51). (B) Analysis of TDP-43 protein expression in colon cancer and normal tissues from the CPTAC database. (n-tumor=97, n-normal=100). (C) Correlation analysis between TARDBP and HIF1A mRNA expression in TCGA CRC samples. The correlation was evaluated using Pearson’s correlation analysis. ⁎⁎⁎P < 0.001.Fig 1 dummy alt text TARDBP is upregulated in colorectal cancer and its expression correlates with HIF1A. (A) Analysis of TARDBP mRNA expression in CRC and adjacent normal tissues from the TCGA database. Data are presented as log2(FPKM+1). Statistical significance was determined by unpaired t-test. (n-tumor=698, n-normal=51). (B) Analysis of TDP-43 protein expression in colon cancer and normal tissues from the CPTAC database. (n-tumor=97, n-normal=100). (C) Correlation analysis between TARDBP and HIF1A mRNA expression in TCGA CRC samples. The correlation was evaluated using Pearson’s correlation analysis. ⁎⁎⁎P < 0.001. Hypoxia induces TDP-43 expression through HIF1-dependent transcriptional regulation in CRC cells Based on the positive clinical correlation observed between TARDBP and HIF1A, we hypothesized that TDP-43 expression is directly controlled by the master hypoxia regulator, HIF1, under hypoxic conditions. Under hypoxic conditions (1% O2), TARDBP mRNA and protein levels were significantly induced in a time-dependent manner in SW480 and HCT116 cells, paralleling the induction of HIF-1α protein (Fig. 2A, B). To investigate if this hypoxic induction is mediated by HIF1, we efficiently knocked down HIF1A using specific shRNAs (Fig. 2C, D). Notably, HIF1A depletion markedly attenuated the hypoxia-induced upregulation of TDP-43 protein (Fig. 2E), indicating that HIF1A is necessary for TDP-43 induction under hypoxia.Fig. 2Hypoxia induces TARDBP expression through HIF1-dependent transcriptional regulation in colorectal cancer cells. (A-B) SW480 and HCT116 cells were exposed to hypoxic conditions (1% O2) for the indicated times. (A) TARDBP mRNA levels were measured by RT-qPCR. Data are normalized to normoxic control (0 h). (B) Protein levels of TDP-43 and HIF-1α were analyzed by Western blotting. β-actin served as a loading control. (C-D) Validation of HIF1A knockdown efficiency in SW480 and HCT116 cells transfected with shRNA targeting HIF1A (shHIF1A) or non-targeting control (shNC). Efficiency was confirmed by (C) RT-qPCR and (D) Western blotting. (E) Western blot analysis of TDP-43 protein levels in SW480 and HCT116 cells transfected with shNC or shHIF1A and then exposed to hypoxia (1% O2, 24 h). (F) Luciferase reporter assay in HEK293T cells co-transfected with a TARDBP promoter reporter construct and either HIF1A overexpression plasmid (HIF1A) or empty vector control (Vec). Firefly luciferase activity was normalized to Renilla luciferase activity. (G) Luciferase activity of serial 5’-truncation mutants of the TARDBP promoter co-transfected with HIF1A into HEK293T cells. The location of putative hypoxia-response elements (HREs) is indicated. (H) ChIP assays were performed in SW480 and HCT116 cells cultured under normoxia or hypoxia (24 h) using an anti-HIF-1α antibody. Precipitated DNA was analyzed by qPCR with primers specific for the three HRE regions in the TARDBP promoter. Enrichment is presented as a percentage of input. *P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001.Fig 2 dummy alt text Hypoxia induces TARDBP expression through HIF1-dependent transcriptional regulation in colorectal cancer cells. (A-B) SW480 and HCT116 cells were exposed to hypoxic conditions (1% O2) for the indicated times. (A) TARDBP mRNA levels were measured by RT-qPCR. Data are normalized to normoxic control (0 h). (B) Protein levels of TDP-43 and HIF-1α were analyzed by Western blotting. β-actin served as a loading control. (C-D) Validation of HIF1A knockdown efficiency in SW480 and HCT116 cells transfected with shRNA targeting HIF1A (shHIF1A) or non-targeting control (shNC). Efficiency was confirmed by (C) RT-qPCR and (D) Western blotting. (E) Western blot analysis of TDP-43 protein levels in SW480 and HCT116 cells transfected with shNC or shHIF1A and then exposed to hypoxia (1% O2, 24 h). (F) Luciferase reporter assay in HEK293T cells co-transfected with a TARDBP promoter reporter construct and either HIF1A overexpression plasmid (HIF1A) or empty vector control (Vec). Firefly luciferase activity was normalized to Renilla luciferase activity. (G) Luciferase activity of serial 5’-truncation mutants of the TARDBP promoter co-transfected with HIF1A into HEK293T cells. The location of putative hypoxia-response elements (HREs) is indicated. (H) ChIP assays were performed in SW480 and HCT116 cells cultured under normoxia or hypoxia (24 h) using an anti-HIF-1α antibody. Precipitated DNA was analyzed by qPCR with primers specific for the three HRE regions in the TARDBP promoter. Enrichment is presented as a percentage of input. *P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. We then investigated whether HIF1 directly regulates TARDBP transcription. Ectopic expression of HIF1A significantly enhanced the activity of a TARDBP promoter-driven luciferase reporter (Fig. 2F). Bioinformatic analysis of the TARDBP promoter identified three putative hypoxia-response elements (HREs). Using a series of 5’ truncation reporter constructs, we found that HIF1A overexpression significantly enhanced luciferase activity in all constructs containing the HRE3 site (HRE1-3, HRE2-3, and HRE3 alone) to a comparable extent, with no statistically significant differences observed among them (Fig. 2G). Since the removal of both HRE1 and HRE2 (as in the HRE3-only construct) did not diminish the transcriptional response, these data indicate that HRE3 is the principal site mediating HIF1-driven transactivation of the TARDBP promoter, while HRE1 and HRE2 are dispensable for this hypoxic induction. To provide direct evidence for this specific binding, we performed ChIP assays. This analysis confirmed that hypoxia significantly enriched the binding of HIF1 specifically to the HRE3 region, but not to other HRE sites, in the TARDBP promoter in both SW480 and HCT116 cells (Fig. 2H). Collectively, these results demonstrate that hypoxia induces TARDBP expression transcriptionally primarily through HIF1 binding directly and specifically to the HRE3 site in its promoter. To further clarify the specificity of this regulatory axis, we investigated whether HIF-2α contributes to TARDBP induction. While HIF-2α protein levels increased under hypoxia, its accumulation was notably delayed compared to the rapid induction of HIF-1α (Fig. S1A). Crucially, although HIF2A knockdown effectively reduced its own protein levels, it failed to attenuate the hypoxia-induced upregulation of TDP-43 in both SW480 and HCT116 cells (Fig. S1B, C). Furthermore, to comprehensively rule out the transcriptional involvement of HIF-2α, we performed ChIP-qPCR scanning across the TARDBP promoter region. The results demonstrated that while HIF-1α exhibited robust enrichment, no significant binding of HIF-2α was detected within the promoter (Fig. S1D). These findings indicate that the hypoxic induction of TDP-43 is specifically and exclusively mediated by the HIF1 signaling axis. The HIF1-TARDBP axis promotes malignant phenotypes and VEGF secretion under hypoxia in CRC cells After confirming the regulatory link between HIF-1α and TDP-43, we sought to evaluate the functional necessity of this axis in mediating hypoxia-driven cancer progression, metastasis, and angiogenesis. To functionally characterize the HIF1- TARDBP axis, we first established efficient TARDBP knockdown and HIF1A overexpression models in SW480 and HCT116 cells, as confirmed by qRT-PCR and Western blotting (Fig. 3A-D). Under hypoxic conditions, TARDBP depletion significantly attenuated hypoxia-induced cell proliferation, migration, and invasion (Fig. 3E-G). Crucially, these suppressive effects were markedly rescued by ectopic expression of HIF1A (Fig. 3E-G), indicating that HIF1 functions upstream of TDP-43 to drive these malignant behaviors.Fig. 3The HIF1-TARDBP axis promotes malignant phenotypes and VEGF secretion under hypoxia in CRC cells. (A-D) Validation of gene manipulation efficiency. SW480 and HCT116 cells were transfected with shRNA targeting TARDBP (shTARDBP) or non-targeting control (shNC) (A, B), or with a HIF1A overexpression plasmid (HIF1A) or empty vector control (Vec) (C, D). Knockdown and overexpression efficiency were confirmed by (A, C) qRT-PCR and (B, D) Western blotting. (E-I) Functional assays were performed in cells subjected to the following treatments: Normoxia, Hypoxia, Hypoxia+shNC, Hypoxia+shTARDBP, Hypoxia+shTARDBP+Vec, Hypoxia+shTARDBP+HIF1A. (E) Cell proliferation was assessed by CCK-8 assay. (F) Cell migration was evaluated by Transwell assay (without Matrigel coating). Representative images (left) and quantitative analysis (right) are shown. (G) Cell invasion was evaluated by Transwell assay (with Matrigel coating). Representative images (left) and quantitative analysis (right) are shown. (H) Angiogenesis was assessed using the CAM assay. Representative images of vessels surrounding implanted cells (left) and quantitative analysis of total vessel length and total branching length (right) are shown. Images were captured at × 40 magnification. (I) Secreted VEGF levels in the cell culture supernatant were measured by ELISA. (J) Western blot analysis of activation markers VCAM-1 and ICAM-1 in HUVECs treated for 24 h with conditioned medium (CM) from SW480 or HCT116 cells subjected to the indicated treatments. ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. For panels E-I, statistical symbols denote comparisons to the Normoxia group (*), Hypoxia+shNC group (#), and Hypoxia+shTARDBP+Vec group (△); For panel J, statistical symbols denote comparisons to the Normoxia-CM group (*), Hypoxia+shNC-CM group (#).Fig 3 dummy alt text The HIF1-TARDBP axis promotes malignant phenotypes and VEGF secretion under hypoxia in CRC cells. (A-D) Validation of gene manipulation efficiency. SW480 and HCT116 cells were transfected with shRNA targeting TARDBP (shTARDBP) or non-targeting control (shNC) (A, B), or with a HIF1A overexpression plasmid (HIF1A) or empty vector control (Vec) (C, D). Knockdown and overexpression efficiency were confirmed by (A, C) qRT-PCR and (B, D) Western blotting. (E-I) Functional assays were performed in cells subjected to the following treatments: Normoxia, Hypoxia, Hypoxia+shNC, Hypoxia+shTARDBP, Hypoxia+shTARDBP+Vec, Hypoxia+shTARDBP+HIF1A. (E) Cell proliferation was assessed by CCK-8 assay. (F) Cell migration was evaluated by Transwell assay (without Matrigel coating). Representative images (left) and quantitative analysis (right) are shown. (G) Cell invasion was evaluated by Transwell assay (with Matrigel coating). Representative images (left) and quantitative analysis (right) are shown. (H) Angiogenesis was assessed using the CAM assay. Representative images of vessels surrounding implanted cells (left) and quantitative analysis of total vessel length and total branching length (right) are shown. Images were captured at × 40 magnification. (I) Secreted VEGF levels in the cell culture supernatant were measured by ELISA. (J) Western blot analysis of activation markers VCAM-1 and ICAM-1 in HUVECs treated for 24 h with conditioned medium (CM) from SW480 or HCT116 cells subjected to the indicated treatments. ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. For panels E-I, statistical symbols denote comparisons to the Normoxia group (*), Hypoxia+shNC group (#), and Hypoxia+shTARDBP+Vec group (△); For panel J, statistical symbols denote comparisons to the Normoxia-CM group (*), Hypoxia+shNC-CM group (#). We next assessed the role of this axis in angiogenesis. TARDBP knockdown impaired the ability of CRC cells to stimulate vessel formation in a CAM assay (Fig. 3H). Mechanistically, hypoxia-induced secretion of the key angiogenic factor VEGF was significantly reduced upon TARDBP silencing, and this reduction was reversed by HIF1A overexpression (Fig. 3I). These findings demonstrate that the HIF1-TARDBP axis is critical for promoting proliferation, migration, invasion, and pro-angiogenic VEGF secretion in CRC cells under hypoxia. To further verify that these effects are specifically driven by the stabilization of HIF-1α, we employed the pharmacological hypoxia mimetic DMOG. Pharmacological stabilization of HIF-1α not only induced TDP-43 expression and activated the TARDBP promoter (Fig. S2A, B) but also significantly promoted cell migration and VEGF secretion, and these effects were effectively reversed by TARDBP knockdown (Fig. S2C, D). These parallel results using a chemical mimetic further strengthen the causal link within the HIF1/TARDBP regulatory axis. Furthermore, to evaluate the impact of this axis on the tumor microenvironment, we investigated whether factors secreted by CRC cells could directly activate endothelial cells. Treatment with conditioned medium (CM) from hypoxic CRC cells significantly upregulated the expression of activation markers VCAM-1 and ICAM-1 in HUVECs (Fig. 3J). Crucially, this induction was markedly attenuated when HUVECs were treated with CM from TDP-43-depleted CRC cells (Fig. 3J). These data confirm that the HIF1/TARDBP axis plays a pivotal role in mediating tumor-endothelial crosstalk and promoting an angiogenic microenvironment. TARDBP knockdown suppresses CRC tumor growth and angiogenesis-related factors in a xenograft model To further validate our in vitro findings in a physiological context, we established a xenograft mouse model to investigate the impact of TARDBP silencing on tumor growth and the expression of metastasis-related factors in vivo. The mice were divided into four groups: Normoxia, Hypoxia, Hypoxia+shNC, and Hypoxia+shTARDBP. Tumor growth was monitored weekly for 35 days. As shown in Fig. 4A, the photographs of tumor-bearing mice are displayed, illustrating the subcutaneous tumor growth. Fig. 4B shows the tumor volume changes over time. The tumor volume in the Hypoxia group increased significantly compared to the Normoxia group, while the Hypoxia+shTARDBP group exhibited a significant reduction in tumor growth compared to the Hypoxia+shNC group. Fig. 4C presents the excised tumors from each group at the end of the experiment. The tumor weight at day 35 was measured and summarized in Fig. 4D. The Hypoxia group had higher tumor weight than the Normoxia group, and the Hypoxia+shTARDBP group had lower tumor weight than the Hypoxia+shNC group. Furthermore, IHC was performed to detect the expression of Ki-67, VEGF, and MMP-9 in tumor tissues (Fig. 4E). The results revealed that the positive staining for Ki-67, VEGF, and MMP-9 was markedly decreased in the Hypoxia+shTARDBP group compared to the Hypoxia+shNC group. In summary, these findings indicate that knockdown of TARDBP suppresses CRC growth and metastasis by inhibiting cell proliferation and angiogenesis-related factors.Fig. 4Knockdown of TARDBP inhibits tumor growth and metastasis in a CRC xenograft model. (A) Representative images of tumor-bearing mice, with insets showing magnified views of subcutaneous tumors. (B) Tumor volume changes over 35 days. (C) Photographs of excised tumors from each group. (D) Tumor weight at day 35. (E) IHC staining for Ki-67, VEGF, and MMP-9 in tumor tissues. Scale bar, 50 μm. ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. Statistical symbols denote comparisons to the Normoxia group (*), Hypoxia+shNC group (#).Fig 4 dummy alt text Knockdown of TARDBP inhibits tumor growth and metastasis in a CRC xenograft model. (A) Representative images of tumor-bearing mice, with insets showing magnified views of subcutaneous tumors. (B) Tumor volume changes over 35 days. (C) Photographs of excised tumors from each group. (D) Tumor weight at day 35. (E) IHC staining for Ki-67, VEGF, and MMP-9 in tumor tissues. Scale bar, 50 μm. ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. Statistical symbols denote comparisons to the Normoxia group (*), Hypoxia+shNC group (#). TRIP6 is a direct functional target of TDP-43 regulated through mRNA stabilization Having established the oncogenic role of the HIF1-TARDBP axis, we next sought to identify the critical downstream effectors through which TDP-43 exerts its functions. Given TDP-43’s well-known role as an RNA-binding protein, we hypothesized that it promotes CRC progression by binding to and regulating the stability of specific target mRNAs. Venn diagram analysis revealed 65 overlapping genes from three datasets, including TDP-43 binding targets, prognosis-related genes in CRC, and differentially expressed genes (DEGs) in CRC (Fig. 5A). Among them, 18 genes were highly expressed in CRC and positively correlated with poor prognosis (as detailed in Table S1). TRIP6, a gene critically involved in metastasis, was selected for further investigation [13,14].Fig. 5TRIP6 is a key downstream target of TDP-43 in CRC. (A) Venn diagram identifying overlapping genes from three independent datasets, including TDP-43 binding targets (predicted by the Starbase database), CRC prognosis-related genes (P < 0.01; from TCGA), and DEGs in CRC (|log2FC|>1, Padj < 0.05; from TCGA). 65 overlapping genes were identified, including 18 candidate oncogenes. (B) RIP-qPCR analysis of TRIP6 mRNA enrichment in RNP complexes immunoprecipitated with anti-TDP-43 antibody or IgG control in SW480 and HCT116 cells. (C) Schematic of the domain structure of wild-type (WT) and truncated HA-tagged TARDBP constructs. (D) Western blot analysis confirming the expression of HA-tagged full-length and truncated TDP-43 proteins in transfected SW480 and HCT116 cells. (E) RIP-qPCR analysis assessing the enrichment of TRIP6 mRNA bound by full-length or truncated TDP-43 proteins. Relative enrichment is shown compared to IgG control. (F) qPCR analysis of TRIP6 mRNA levels in SW480 and HCT116 cells transfected with shNC or shTARDBP. (G) qPCR analysis confirming TARDBP overexpression efficiency in SW480 and HCT116 cells transfected with empty vector (Vec) or TDP-43 overexpression plasmid. (H) qPCR analysis of TRIP6 mRNA levels in cells from (G). (I) Western blot analysis of TRIP6 protein levels in SW480 and HCT116 cells transfected with shNC or shTARDBP. (J) Western blot analysis of TDP-43 and TRIP6 protein levels in SW480 and HCT116 cells transfected with Vec or TARDBP overexpression plasmid. (K) TRIP6 mRNA stability assay. SW480 and HCT116 cells transfected with shNC or shTARDBP were treated with actinomycin D (Act D), and TRIP6 mRNA levels were measured by qPCR at the indicated time points. *P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001.Fig 5 dummy alt text TRIP6 is a key downstream target of TDP-43 in CRC. (A) Venn diagram identifying overlapping genes from three independent datasets, including TDP-43 binding targets (predicted by the Starbase database), CRC prognosis-related genes (P < 0.01; from TCGA), and DEGs in CRC (|log2FC|>1, Padj < 0.05; from TCGA). 65 overlapping genes were identified, including 18 candidate oncogenes. (B) RIP-qPCR analysis of TRIP6 mRNA enrichment in RNP complexes immunoprecipitated with anti-TDP-43 antibody or IgG control in SW480 and HCT116 cells. (C) Schematic of the domain structure of wild-type (WT) and truncated HA-tagged TARDBP constructs. (D) Western blot analysis confirming the expression of HA-tagged full-length and truncated TDP-43 proteins in transfected SW480 and HCT116 cells. (E) RIP-qPCR analysis assessing the enrichment of TRIP6 mRNA bound by full-length or truncated TDP-43 proteins. Relative enrichment is shown compared to IgG control. (F) qPCR analysis of TRIP6 mRNA levels in SW480 and HCT116 cells transfected with shNC or shTARDBP. (G) qPCR analysis confirming TARDBP overexpression efficiency in SW480 and HCT116 cells transfected with empty vector (Vec) or TDP-43 overexpression plasmid. (H) qPCR analysis of TRIP6 mRNA levels in cells from (G). (I) Western blot analysis of TRIP6 protein levels in SW480 and HCT116 cells transfected with shNC or shTARDBP. (J) Western blot analysis of TDP-43 and TRIP6 protein levels in SW480 and HCT116 cells transfected with Vec or TARDBP overexpression plasmid. (K) TRIP6 mRNA stability assay. SW480 and HCT116 cells transfected with shNC or shTARDBP were treated with actinomycin D (Act D), and TRIP6 mRNA levels were measured by qPCR at the indicated time points. *P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. RIP assays confirmed the binding between TDP-43 and TRIP6 mRNA in both SW480 and HCT116 cells, as evidenced by significant enrichment of TRIP6 mRNA in anti-TDP-43 immunoprecipitates compared to IgG control (Fig. 5B). To map the specific domains responsible for this interaction, we constructed a series of HA-tagged TARDBP truncation mutants (Fig. 5C), whose expression was verified by western blotting (Fig. 5D). Subsequent RIP-qPCR assays demonstrated that deletion of either the RRM1 (105-169 aa) or RRM2 (193-262 aa) domain markedly reduced the enrichment of TRIP6 mRNA, indicating both RRM domains are essential for the TDP-43/TRIP6 mRNA interaction (Fig. 5E). We further evaluated the regulatory effect of TDP-43 on TRIP6 expression. Knockdown of TARDBP significantly decreased both TRIP6 mRNA (Fig. 5F) and protein levels (Fig. 5I). Conversely, overexpression of TDP-43 led to a substantial increase in TRIP6 mRNA (Fig. 5H, with overexpression efficiency shown in Fig. 5G) and protein expression (Fig. 5J). Furthermore, actinomycin D chase assays revealed that TARDBP knockdown accelerated the decay of TRIP6 mRNA (Fig. 5K), indicating that TDP-43 enhances TRIP6 expression by stabilizing its mRNA. In summary, these results demonstrate that TRIP6 is a direct functional target of TDP-43, whose expression and mRNA stability are positively regulated by TDP-43 through an interaction requiring its RRM1 and RRM2 domains. TDP-43 promotes malignant phenotypes and angiogenesis in CRC through TRIP6 Finally, to confirm whether TRIP6 is the primary mediator of TDP-43’s pro-oncogenic effects, we performed rescue experiments to determine if restoring TRIP6 expression could counteract the anti-tumor and anti-angiogenic effects of TARDBP silencing under hypoxia. In both SW480 and HCT116 cells, knockdown of TARDBP significantly suppressed hypoxia-induced cell proliferation (Fig. 6A), migration (Fig. 6B), and invasion (Fig. 6C). Crucially, these inhibitory effects were markedly reversed by ectopic expression of TRIP6 (Fig. 6A-C). We next assessed the role of the TDP-43-TRIP6 axis in angiogenesis. In the CAM assay, TARDBP depletion impaired hypoxia-induced angiogenesis, as evidenced by reduced total vessel length and branching points. This impairment was significantly rescued by TRIP6 overexpression (Fig. 6D, E). Consistent with this pro-angiogenic function, the secretion of VEGF, a critical angiogenic factor, was reduced by TARDBP knockdown but restored upon TRIP6 reconstitution (Fig. 6F). These rescue experiments demonstrate that the promotive effects of TDP-43 on CRC malignancy and angiogenesis under hypoxia critically depend on its downstream target TRIP6.Fig. 6TDP-43 promotes malignant phenotypes and angiogenesis in CRC through TRIP6. SW480 and HCT116 cells were subjected to the following treatments under hypoxia (1% O2): Hypoxia, Hypoxia+shTARDBP, Hypoxia+shTARDBP+Vec, Hypoxia+shTARDBP+TRIP6. (A) Cell proliferation was assessed by CCK-8 assay. (B) Cell migration was evaluated by Transwell assay (without Matrigel). (C) Cell invasion was evaluated by Transwell assay (with Matrigel). Representative images (left) and quantitative analysis (right) are shown for (B) and (C). (D) Representative images of angiogenesis in the CAM assay. Images were captured at × 40 magnification. (E) Quantitative analysis of total vessel length and total branching length from the CAM assay shown in (D). (F) Secreted VEGF levels in the cell culture supernatant were measured by ELISA. *P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. Statistical symbols denote comparisons to the Hypoxia group (*), Hypoxia+shTARDBP+Vec group (#).Fig 6 dummy alt text TDP-43 promotes malignant phenotypes and angiogenesis in CRC through TRIP6. SW480 and HCT116 cells were subjected to the following treatments under hypoxia (1% O2): Hypoxia, Hypoxia+shTARDBP, Hypoxia+shTARDBP+Vec, Hypoxia+shTARDBP+TRIP6. (A) Cell proliferation was assessed by CCK-8 assay. (B) Cell migration was evaluated by Transwell assay (without Matrigel). (C) Cell invasion was evaluated by Transwell assay (with Matrigel). Representative images (left) and quantitative analysis (right) are shown for (B) and (C). (D) Representative images of angiogenesis in the CAM assay. Images were captured at × 40 magnification. (E) Quantitative analysis of total vessel length and total branching length from the CAM assay shown in (D). (F) Secreted VEGF levels in the cell culture supernatant were measured by ELISA. *P < 0.05, ⁎⁎P < 0.01, ⁎⁎⁎P < 0.001. Statistical symbols denote comparisons to the Hypoxia group (*), Hypoxia+shTARDBP+Vec group (#). Discussion CRC progression is strongly influenced by the hypoxic tumor microenvironment [15], yet the complete molecular mechanisms linking hypoxia to malignant phenotypes remain incompletely understood [15,16]. In this study, we systematically addressed our research objectives to elucidate these mechanisms, establishing a clear logical framework for our experimental design. First, we successfully identified the upstream regulation where HIF1 transcriptionally upregulates TARDBP through direct binding to a specific HRE3 in its promoter, fulfilling our first objective. Second, our functional assays provided robust evidence for the necessity of the HIF1/TARDBP axis in driving malignant phenotypes, including proliferation, migration, invasion, and angiogenesis, both in vitro and in vivo, addressing our second objective. Finally, we characterized TRIP6 as the critical downstream mediator that fulfills our third objective. Together, these findings define a novel HIF1/TARDBP/TRIP6 signaling cascade that orchestrates the adaptive response of CRC cells to hypoxia. The clinical significance of this axis is underscored by the direct correlation between hypoxia severity and tumor aggressiveness. Previous longitudinal imaging has shown that the onset and sustained presence of hypoxia strongly correlate with increased incidence of metastasis and unfavorable prognosis in cancer patients [4,6]. By establishing the HIF1/TARDBP/TRIP6 cascade, we provide a concrete molecular link between the clinically observed hypoxic state and the aggressive metastatic behavior of CRC. While TDP-43 has been primarily studied in neurodegenerative diseases [17,18], emerging evidence underscores its role as a multifaceted RNA-binding protein that drives cancer progression through diverse post-transcriptional mechanisms. TDP-43 regulates gene expression by modulating alternative splicing, mRNA stability, miRNA biogenesis, and lncRNA interactions [10]. For example, in triple-negative breast cancer, TDP-43 complexes with SRSF3 to alter the splicing of tumor suppressors such as PAR3 and NUMB, thereby promoting metastasis [19]. In lung cancer, it enhances malignancy by stabilizing the oncogenic lncRNA MALAT1 [20] and processing miR-423-3p [21]. Similarly, in hepatocellular carcinoma, TDP-43 suppresses the miR-520 family to upregulate PFKP and accelerate glycolysis [22]. Although direct evidence in colorectal cancer is still evolving, TDP-43-mediated splicing regulation of CFTR suggests a plausible role in tumor suppression [23], which our current study further explores under hypoxic conditions. Our work extends the oncogenic repertoire of TDP-43 by identifying it as a direct effector of the canonical hypoxic response pathway in CRC, specifically localized downstream of HIF1. The most significant mechanistic advance of this study concerns the identification of TRIP6 as the functional bridge between TDP-43 and CRC malignancy. TRIP6 is a multifunctional adaptor protein belonging to the zyxin family of LIM domain-containing proteins [24]. It localizes primarily to focal adhesions and the actin cytoskeleton, where it serves as a scaffolding platform that recruits diverse signaling molecules to regulate cell adhesion, motility, and survival through multidomain-mediated protein-protein interactions [[25], [26], [27]]. TRIP6 can also shuttle to the nucleus and function as a transcriptional co-regulator, underscoring its role as a versatile signaling hub coordinating cellular responses across compartments [28,29]. TRIP6 has been consistently implicated in promoting metastasis across multiple cancers, including colorectal cancer where it disrupts tight junctions by interacting with PARD3 to facilitate tumor dissemination and chemoresistance [30]. By identifying that TDP-43 stabilizes TRIP6 mRNA via its RNA recognition motifs, we provide a direct molecular link between hypoxia sensing and the activation of pro-invasive cellular machinery. The functional significance of this axis was confirmed through comprehensive rescue experiments, fulfilling our third research objective. These findings have important clinical implications. The consistent upregulation of this signaling axis in CRC tumors suggests that targeting components of the HIF1/TARDBP/TRIP6 pathway could represent a viable therapeutic strategy, particularly for hypoxic, aggressive CRC subtypes. Given the challenges in directly targeting HIF-1α, TDP-43 or its interaction with TRIP6 mRNA might offer more accessible therapeutic targets. Furthermore, the expression levels of these factors could serve as prognostic biomarkers for identifying high-risk CRC patients. Several limitations of our study should be acknowledged. The functional assessment of this axis in metastasis relied primarily on xenograft models, and its role in spontaneous metastasis from orthotopic tumors requires further investigation. The clinical relevance of our findings needs validation in larger, independent patient cohorts. Additionally, while we focused on TRIP6, it is likely that TDP-43 regulates other mRNAs under hypoxia that contribute to the malignant phenotype. A comprehensive analysis of the TDP-43-bound transcriptome in hypoxic CRC cells would provide a more complete understanding of its regulatory network. In conclusion, by systematically pursuing our defined experimental objectives, we have identified a linear pathway wherein hypoxia activates HIF1, which transcriptionally induces TARDBP. TDP-43, in turn, stabilizes TRIP6 mRNA through direct binding, leading to enhanced TRIP6 protein expression that drives CRC cell migration, invasion, and angiogenesis. This study not only deepens our understanding of hypoxia-mediated CRC progression but also highlights the HIF1/TARDBP/TRIP6 axis as a promising therapeutic target for advanced CRC. Author contributions Ke Cheng was responsible for the methodology design and overall supervision, and also wrote the original draft and participated in the review and editing of the manuscript. Bin Hao contributed to the conceptualization and took part in writing and revising the original draft. Yonggang Liu conducted the formal analysis, data curation and project administration. Weiyu Feng was responsible for visualization and performed the validation. Dongli Xu visualization and managed the data. Competing interests The authors declared that there are no competing interests. Data availability The data and material presented in this manuscript is available from the corresponding author on reasonable request. Ethical approval All animal experiments were performed with the approval of the Institutional Animal Care and Use Committee (IACUC) of the Second Clinical College of Zhengzhou University and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Consent for publication I confirm that any participants (or their guardians if unable to give informed consent, or next of kin, if deceased) who may be identifiable through the manuscript (such as a case report), have been given an opportunity to review the final manuscript and have provided written consent to publish. Funding Not applicable. CRediT authorship contribution statement Ke Cheng: Writing – review & editing, Writing – original draft, Supervision, Methodology. Yonggang Liu: Project administration, Formal analysis, Data curation. Weiyu Feng: Visualization, Validation. Dongli Xu: Visualization, Data curation. Bin Hao: Writing – review & editing, Writing – original draft, Conceptualization. Declaration of competing interest The authors declare that they have no conflict of interest.